UPDATE: Oppenheimer Downgrades Zogenix to Perform Following Negative Panel
Oppenheimer reduced its rating on Zogenix (NASDAQ: ZGNX) from Outperform to Perform and removed its $3 price target.
Oppenheimer said, "On 12/7, ZGNX's Zohydro did not receive a positive recommendation from an FDA Advisory Committee, which cited safety concerns, mainly abuse potential and dependence. It appeared that the panel held Zohydro to a higher standard than other in-class drugs. As such, we do not anticipate that ZGNX will receive approval by the 3/1/13 PDUFA with potential approval likely delayed until abuse risks are mitigated. We believe ZGNX will continue to work with the FDA to improve upon the current REMS program, which the panel viewed as insufficient (owing mainly to its voluntary nature)."
Zogenix closed at $2.36 on Friday.
Latest Ratings for ZGNX
|Nov 2016||Aegis Capital||Initiates Coverage On||Buy|
|Oct 2016||Leerink Swann||Assumes||Outperform|
|Nov 2015||Leerink Swann||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.